Table 3. In vitro antiproliferative activity (TGI) a of hybrid compounds 8a–o.
| Hybrid | UACC-62 | U251 | MCF7 | NCI/ADR-RES | 786-0 | NCI-H460 | PC-3 | OVCAR-3 | HT29 | HaCaT |
| 8a | 19.18 | 12.43 | 43.14 | >100 | 97.08 | >100 | 92.21 | 6.90 | 77.13 | 165.69 |
| 8b | 22.92 | 12.19 | 42.52 | >100 | 39.67 | >100 | >100 | 18.45 | 73.42 | 507.82 |
| 8c | >100 | >100 | >100 | >100 | >100 | >100 | >100 | 81.19 | >100 | 294.37 |
| 8d | 37.75 | 98.09 | >100 | >100 | >100 | >100 | >100 | 13.45 | >100 | 79.75 |
| 8e | 26.73 | 11.34 | 82.50 | >100 | 87.34 | >100 | 54.39 | 53.76 | >100 | 75.76 |
| 8f | 20.50 | 19.99 | 28.97 | >100 | 23.26 | 78.17 | 49.27 | 32.65 | 62.63 | 44.47 |
| 8g | 31.56 | 30.52 | 42.96 | >100 | 44.08 | >100 | 49.76 | 13.33 | 86.22 | 115.66 |
| 8h | 34.23 | 30.21 | 68.70 | >100 | 80.31 | 83.14 | 62.01 | 34.31 | 79.55 | 29.51 |
| 8i | >100 | >100 | >100 | 84.90 | >100 | >100 | >100 | >100 | 95.99 | 486.19 |
| 8j | 3.83 | 77.91 | 53.26 | 80.17 | 88.09 | >100 | 85.69 | 48.03 | 94.95 | 147.92 |
| 8k | 29.94 | 6.61 | >100 | >100 | 53.16 | >100 | 23.98 | 29.34 | >100 | 436.18 |
| 8l | 20.92 | 25.97 | 30.97 | >100 | >100 | 51.61 | 21.87 | >100 | 48.99 | 36.44 |
| 8m | 26.47 | 26.98 | 44.95 | >100 | 26.67 | 38.72 | 21.68 | 11.81 | 28.95 | 78.72 |
| 8n | 62.01 | 8.28 | 44.81 | >100 | >100 | >100 | 79.92 | >100 | >100 | 451.02 |
| 8o | 86.16 | 44.04 | 91.94 | >100 | >100 | >100 | >100 | 94.99 | >100 | 71.34 |
| Dox | 1.66 | 0.09 | 0.99 | 0.78 | 0.02 | 0.46 | 15.69 | 0.04 | 0.88 | 1.47 |
aThe concentration that elicits total growth inhibition (TGI, in μM) was determined from a non-linear regression analysis using ORIGIN 8.0® (OriginLab Corporation). The experiments were conducted in triplicate. Dox: doxorubicin, positive control.